Several Wall Street firms updated their price targets on healthcare, diagnostics, automotive and semiconductor-related companies on Monday, with Evercore ISI making a series of adjustments across the MedTech, Life Sciences Tools and Diagnostics sectors.
Evercore ISI lowered its price target on Intuitive Surgical (ISRG) to $430 from $480 while maintaining an “In Line” rating on the shares. The firm said its second-quarter preview for the MedTech, Life Sciences Tools and Diagnostics sectors points to generally healthy procedure volumes and capital expenditure trends across the industry.
The firm also reduced its price target on iRhythm Technologies (IRTC) to $150 from $160, while keeping an “Outperform” rating on the stock. Evercore ISI analyst Vijay Kumar cited the same broader sector backdrop, noting that procedure volumes and capital spending trends remain broadly constructive heading into second-quarter earnings.
In contrast, Evercore ISI raised its price target on Illumina (ILMN) to $200 from $155 and reiterated an “Outperform” rating. The revision reflects a more positive view on the company’s outlook within the diagnostics and life sciences tools space.
Natera (NTRA) also saw its price target increased by Evercore ISI, with the firm lifting its target to $300 from $270 and maintaining an “Outperform” rating. The update comes as investor attention remains focused on growth trends across genetic testing and diagnostics companies.
Evercore ISI additionally raised its price target on Mettler-Toledo (MTD) to $1,350 from $1,300, while keeping an “Outperform” rating on the shares. The firm’s broader sector preview suggests continued resilience in capital expenditure trends, despite a mixed macroeconomic environment.
Separately, Deutsche Bank lowered its price target on Adient (ADNT) to $29 from $31 ahead of the company’s fiscal third-quarter earnings, while maintaining a “Buy” rating on the shares.
Deutsche Bank also raised its price target on Entegris (ENTG) to $155 from $145, keeping a “Hold” rating on the stock. Analyst Melissa Weathers said the firm is raising estimates due to signs of cycle improvement, but added that much of the positive outlook appears to already be reflected in the share price.
